Key takeaways
- Accelerated approvals on small-cap biotechs produce the biggest single-day gaps, while standard approvals on large caps barely move because the outcome is already priced in.
- An FDA approval moves a stock in three phases: a run-up into the decision, a gap on the headline, and either a fade or multi-day continuation.
- PDUFA dates are public months ahead, so positioning builds early and the approval itself often gaps less than an unscheduled NDA approval.
- The first 30 minutes after the headline usually set the high or low of the day, and the initial move is the only one with clean liquidity.
- An approval is only tradeable when it surprises; when it merely confirms a priced-in expectation, approval day becomes the exit liquidity event.
The stocks that skyrocketed after FDA approval did so through a predictable set of mechanics: a run-up into the decision, a gap on the headline, then either continuation or a fade that starts within the first hour. This breakdown pairs the biggest single-day surges with their approval type and move structure, so you can map the catalyst to the trade instead of reacting to the ticker.
Which stocks skyrocketed the most after FDA approval?
The biggest single-day movers share one trait: the approval was the primary source of the trade, not a headline someone summarized after the fact. You can verify each drug and date yourself in the FDA press announcements archive.
| Stock | Drug | Approval type | Approx. move |
|---|---|---|---|
| Portola (PTLA) | Andexxa, May 2018 | Accelerated approval | Roughly doubled |
| Intercept (ICPT) | Ocaliva, May 2016 | Accelerated approval | Large double-digit gap |
| Sarepta (SRPT) | Elevidys, June 2023 | Accelerated approval | Strong gap, then continuation |
| Gilead (GILD) | Veklury, Oct 2020 | Standard approval | Modest, largely priced in |
| Vertex/CRISPR | Casgevy, Dec 2023 | Standard approval | Muted, expected |
The pattern in the table is the trade: accelerated approvals on small-cap biotechs produced the violent gaps, while standard approvals on large caps barely moved because the outcome was already priced in. That is the same asymmetry you see on macro prints — the CPI release moves NQ and ES in seconds because the number is the catalyst (how CPI affects stocks). The approval type, not the headline, tells you whether the move is tradeable.
How does an FDA approval actually move a stock price?
An FDA approval moves a stock in three distinct phases: a run-up into the decision, a gap on the headline, and then either a fade or a multi-day continuation. Each phase has different mechanics, and each rewards a different trade.
The run-up before the decision
Catalyst traders know the move often starts before the headline. Expectations leak: advisory committee votes, PDUFA calendar dates, and analyst previews all push positioning into the stock ahead of the decision. By the time the approval hits the wire, part of the move is already priced in, which is exactly why the gap size matters more than the headline itself.
The gap and the first 30 minutes
The headline triggers a gap, then a volume spike as market orders and stop runs clear. The first 30 minutes usually set the high or low of the day: wide spreads, erratic prints, and a battle between pre-positioned sellers taking profit and new money chasing the catalyst. If you trade the initial move, your edge is speed to the primary source, not the summary someone posts ten minutes later.
Fade vs. continuation
Approvals that come with raised guidance, expanded indications, or surprise commercial detail tend to continue for days. Approvals that were fully expected tend to fade the gap as early buyers exit. Watch whether price holds above the gap fill level on declining volume: that tells you whether the catalyst created a new baseline or just a spike.
The same timing logic applies across asset classes, not just biotech. Macro headlines move NQ and ES the same way a PDUFA date moves a small cap, which is why reading volatility around scheduled events matters. Our breakdown of what is VIX covers how implied volatility behaves around catalyst windows.
NDA vs BLA vs PDUFA: does the approval type change the trade?
Yes, because each pathway has a different information schedule, and the market reacts to the schedule as much as the science. NDA and BLA approvals are binary events with no fixed calendar, so they produce gap risk you cannot time. PDUFA dates and advisory committee votes are on the calendar months ahead, so the run-up and the "priced in" problem are baked in before the catalyst hits.
NDA approvals
New Drug Applications cover small-molecule drugs. Because the FDA has no statutory deadline to announce, the approval can land any business day, and the tape is the first confirmation. That is the trade: you are front-running the headline, not the science.
BLA approvals
Biologics License Applications carry the same uncertainty but add manufacturing scrutiny, so rejections and complete response letters are more common surprises. Treat a BLA decision as a coin you cannot see until it lands.
PDUFA dates and AdCom votes
The long paragraph worth quoting on its own: a PDUFA date is the FDA's goal date for a decision under the Prescription Drug User Fee Act, and it changes the entire structure of the trade. Because the date is public, positioning builds for weeks, the pre-approval run-up absorbs part of the expected move, and the approval itself often gaps less than an unscheduled NDA would. An AdCom vote a few months earlier acts as a dry run: a positive committee outcome typically produces a smaller, tradable spike and shifts odds for the PDUFA decision, while a negative vote can erase the run-up in one session. The same logic applies to scheduled macro catalysts, which is why the mechanics of trading a known FOMC calendar date (https://trytradar.com/learn/how-to-trade-fomc-meeting) map almost one-to-one onto PDUFA dates. Accelerated approval sits between the two: it is still unscheduled, but it usually applies to drugs with surrogate-endpoint data already public, so the surprise gap tends to be smaller than a standard NDA approval on the same market cap. Historical single-day moves for each pathway are documented in exchange price data, e.g. Nasdaq historical market data.
Case study: the classic single-day approval spike pattern
The textbook setup looks like this: a small biotech with one lead asset runs up into a PDUFA date, the stock gaps at the open on the approval headline, volume concentrates in the first 15 to 30 minutes, and the day resolves as continuation or fade depending on whether the label language surprised anyone.
The mechanics matter more than the ticker. The pre-approval run-up tells you how much was already expected; the gap size tells you what the headline added; the first hour's volume tells you whether institutions are building or distributing. If the label comes back with a narrower indication or an added boxed warning, the gap fades by midday even though the approval itself was "good news."
If you're trading futures all day and only touch single names on catalyst days, the honest framing is that this is a different skill set with different risk: single-name gaps can move 30 to 80 percent in a session (illustrative of the pattern class, not a promise), and the initial move is the only one with clean liquidity. Our own Tradar alerts are built for macro catalysts on NQ and ES first; single-stock FDA coverage is thinner, and we say so. If you want the broader mechanics before risking a name, start with how to start trading stocks, then watch one PDUFA date end to end before you trade it.
Case study: when the approval was already priced in
The most instructive FDA trades are the ones that barely move. When a PDUFA date is public and every desk has modeled the outcome for months, the run-up does the work: the stock grinds higher into the decision, then the approval headline lands and produces a gap that immediately fades. Traders who bought the headline bought the top of the expectation curve, not the catalyst.
The mechanism matters. An NDA, a BLA, and an advisory committee vote each carry different certainty profiles, which is why the FDA's own overview of drug approval pathways (How Drugs Are Developed and Reviewed) is worth reading before you size a position. A committee vote that leaks favorably weeks before the decision leaves almost nothing for the approval day.
The same expectation logic applies outside biotech: an FOMC cut that everyone saw coming produces a fade, not a trend (how Fed rate decisions affect markets). Trade the surprise, not the headline.
Why do some FDA approval stocks fade after the gap?
The fade usually comes down to one question: was the approval the catalyst, or the confirmation? If the run-up already priced the decision in, approval day becomes the exit liquidity event. Traders who bought the rumor sell the news into the gap, volume spikes at the open, and the stock closes well off its high. That is a one-day pop, not a re-rating.
The second fade trigger is what management does after the approval. Pricing announcements, dilutive offerings, and cash-burn guidance frequently land within days of the decision, and a small-cap biotech that just validated its pipeline is the most dilution-prone company on the tape. You can check the approval record itself, including the label scope and any post-marketing requirements, in the FDA drug approval databases before the open.
The tell is in the first hour. A re-rating holds its gap and builds on it with sustained volume; a fade prints a tall red candle by 10:30. If the label is narrower than the trial data implied, treat the pop as the trade and move on.
How do you find FDA approval catalysts before the move?
The workflow has three parts: know the dates before the market does, read the primary source first, and get the headline on your screen in under a minute. If a creator video or a Discord ping is your first look, the first 5 to 10 percent of the move is already gone.
Tracking PDUFA dates
PDUFA dates are public. FDA publishes advisory committee calendars, and companies disclose goal dates in their own 8-Ks and press releases. Build a simple calendar of upcoming decisions for the tickers you actually trade, split by mechanism: NDA, BLA, accelerated approval, or adcomm vote. Each converts differently, so tag the event type when you log it.
Then do the harder part: for each date, write down what "priced in" looks like. If a stock has run 40% into a decision, the gap trade may already be crowded, and continuation depends on the label language, not the approval itself.
Getting the headline in under a minute
The information edge belongs to whoever reaches the primary source first. FDA posts decisions on its own site, but checking it manually during the session costs you the initial move.
This is the gap Tradar is built for: real-time alerts that surface the catalyst headline while the tape is still forming, so you trade the move instead of the recap. Honest limitation: no alert service beats reading the FDA docket yourself if you already know the exact second a decision drops. Alerts earn their keep across a watchlist of dozens of dates you cannot personally watch. Pair the alert with your pre-written plan: gap size you'll accept, fade vs. continuation criteria, and the volume profile that confirms the move is real.
FAQ
How much does a stock typically go up after FDA approval?
There is no typical move. Accelerated approvals on small-cap biotechs have roughly doubled in a session, like Portola on Andexxa in May 2018, while standard approvals on large caps like Gilead's Veklury barely moved because the outcome was already priced in. Gap size depends on approval type and how much the pre-approval run-up absorbed.
Do stocks always go up after FDA approval?
No. When a PDUFA date is public and the run-up already priced the decision in, approval day becomes the exit liquidity event and the gap fades. Narrower label language or an added boxed warning can also kill the move by midday. The approval is only tradeable when it surprises, not when it confirms.
What is a PDUFA date and why does it matter for trading?
A PDUFA date is the FDA's goal date for a decision under the Prescription Drug User Fee Act. Because it is public months ahead, positioning builds for weeks, the run-up absorbs part of the expected move, and the approval itself often gaps less than an unscheduled NDA would. It changes the entire structure of the trade.
Is it too late to buy a biotech stock after the approval headline?
Often yes. The first 30 minutes usually set the high or low of the day, and the initial move is the only one with clean liquidity. Watch whether price holds above the gap fill level on declining volume: continuation approvals build on the gap, while expected ones fade as early buyers exit into the spike.